JPRN-UMIN000044778已完成未知
A feasibility study of Niraparib in patient with recurrent epithelial ovarian cancer after Olaparib maintenance therapy - NAO study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients with persistent Grade 3 or higher toxicity from previous chemotherapy 2. Patients with untreated double cancer 3. Patients with brain metastases or pial meningeal metastases 4. Patients who have undergone ascites drainage since the start of the last two cycles of chemotherapy 5. Patients who are hypersensitive to the components of the study drug or its related compounds 6. Patients who have previously received PARP inhibitors for the treatment of other diseases 7. Patients who underwent major surgery (at the discretion of the investigator) within 3 weeks before the first dose. The patient must have recovered from all the effects of major surgery. 8. Patients at high medical risk due to uncontrolled serious illness, non-malignant systemic illness, or uncontrolled active infection. 9. Patients with any disease, treatment or laboratory abnormalities that affect the test results [myelosuppression with poor control (anemia, leukocyte depletion, neutropenia or thrombocytopenia), etc.] 10. Women who are pregnant, planning to become pregnant, or breastfeeding. However, if a lactating woman stops breastfeeding, she can register. 11. Immunosuppressed patients (patients undergoing splenectomy are acceptable) 12. Patients known to be positive for human immunodeficiency virus (HIV) 13. Patients with known or suspected hepatitis B virus surface antigen (HBsAg) positive or active hepatitis C virus (HCV) infection Note: Patients with hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled, but hepatitis B virus (HBV) must be below the detection limit. Patients who are positive for hepatitis C virus antibody (HCVAb) must have HCV below the detection limit.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-BEJanssen-Cilag International NV140
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-GBJanssen-Cilag International NV140
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with JNJ-63723283 in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ESJanssen-Cilag International NV60
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ITJANSSEN CILAG INTERNATIONAL NV140
已完成
2 期
A feasibility study of niraparib for advanced, BRCA1-like, HER2-negative breast cancer patients: the ABC studymetastastic10006291breast cancerNL-OMON47829ederlands Kanker Instituut39